PACB - Pacific Biosciences of California Inc. (PACB) Q4 2023 Earnings Call Transcript
2024-02-15 18:39:09 ET
Pacific Biosciences of California, Inc. (PACB)
Q4 2023 Earnings Conference Call
February 15, 2024 05:00 PM ET
Company Participants
Todd Friedman - Senior Director, Investor Relations
Christian Henry - President & Chief Executive Officer
Susan Kim - Chief Financial Officer
Conference Call Participants
Dan Brennan - TD Cowen
Kyle Mikson - Canaccord
John Sourbeer - UBS
Jack Meehan - Neffron Research
Doug Schenkel - Wolfe Research
Sung Ji Nam - Scotiabank
Eve Burstein - Bernstein Research
Ross Osborn - Cantor Fitzgerald
Tejas Savant - Morgan Stanley
Subbu Nambi - Guggenheim
Rachel Vatnsdal - JPMorgan
Mason Carrico - Stephens
Presentation
Operator
Hello and welcome to the PacBio Fourth Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]
I would now like to hand the call to Todd Friedman, Senior Director, Investor Relations. Please go ahead.
Todd Friedman
Good afternoon and welcome to PacBio’s fourth quarter 2023 earnings conference call.
Earlier today, we issued a press release outlining the financial results, we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov .
With me today are Christian Henry, President and Chief Executive Officer and Susan Kim, Chief Financial Officer.
On today's call, we will make forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations with respect to our growth potential, instrument and consumable sales, and GAAP and non-GAAP growth guidance.
You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed....
Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript